{"id":"tedizolid-phophate","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL2105669","moleculeType":"Small molecule","molecularWeight":"450.32"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tedizolid phosphate works by binding to the 50S ribosomal subunit of bacteria, which prevents the formation of the 70S initiation complex and thereby inhibits protein synthesis. This action is bacteriostatic, meaning it prevents the growth and replication of bacteria, rather than killing them outright. As a result, tedizolid phosphate is effective against a wide range of Gram-positive bacteria, including MRSA.","oneSentence":"Tedizolid phosphate is an oxazolidinone antibiotic that inhibits protein synthesis in bacteria by binding to the 50S ribosomal subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:44.010Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bacterial skin and skin structure infections (ABSSSI)"}]},"trialDetails":[{"nctId":"NCT02444234","phase":"PHASE4","title":"Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2015-07","conditions":"Cystic Fibrosis","enrollment":11},{"nctId":"NCT02276482","phase":"PHASE3","title":"Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2015-03-25","conditions":"Skin Diseases, Infectious, Skin Diseases, Bacterial","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TR701-122","MK-1986","SIVEXTRO®"],"phase":"phase_3","status":"active","brandName":"Tedizolid Phophate","genericName":"Tedizolid Phophate","companyName":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","companyId":"cubist-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tedizolid phosphate is an oxazolidinone antibiotic that inhibits protein synthesis in bacteria by binding to the 50S ribosomal subunit. Used for Acute bacterial skin and skin structure infections (ABSSSI).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}